PlainPharmaWatch

CMS Open Payments · Program Year 2024

Scpharmaceuticals Inc.

Scpharmaceuticals Inc. reported $1,622,083.11 across General Payments, Research, and Ownership to 13,366 physicians and teaching hospitals across 13,372 transactions.

$1.6M
All-tracks total
13,372
Transactions
13,366
Recipients
+$342.2K
General Payments vs PY2023

Scpharmaceuticals Inc. reported $1,622,083.11 across all CMS Open Payments tracks (General + Research + Ownership) to 13,366 physicians and teaching hospitals in Program Year 2024 - ranking #500 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $980,363.67, averaging $121.36 per recipient.

Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.

CMS Sunshine Act warrant

Manufacturer scpharmaceuticals-inc Scpharmaceuticals Inc.

$1.6M · #500/1,925 · 0.0% industry · PY2024

  • TOT $1.6M
  • RANK #500
  • SHARE 0.0%
  • TXN 13,372
  • RCP 13,366
  • CAT 6
  • GEN $980.4K
  • ΔGEN +$342.2K
  • TOP1 4.6%
  • PY 2024

Nearest volume peer: Terumo Medical Corporation ($1.6M)

Menarini Silicon Biosystems,…$1.6MTerumo Medical Corporation$1.6MScpharmaceuticals Inc. (this)$1.6MEndologix LLC$1.6MSmartPractice Allergen Bank,…$1.6M
All-tracks payment totals near Scpharmaceuticals Inc. (CMS Open Payments PY2024)

Scpharmaceuticals Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →

Release-over-release change

General Payments changed from PY2023 to PY2024

Scpharmaceuticals Inc.'s CMS-reported General Payments increased by $342.2K (+53.6%) from PY2023 to PY2024.

How this year-over-year comparison is scoped

The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.

CMS source labels for this exact identifier: PY2023: SCPHARMACEUTICALS INC.PY2024: SCPHARMACEUTICALS INC.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.

Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.

General Payments: PY2023 vs PY2024

Annual CMS-reported totals for this company, not an all-category Open Payments total

PY2023$638.2KPY2024$980.4K
PY2023
$638,170.44
PY2024
$980,363.67

What the Data Shows for Scpharmaceuticals Inc.

Averaging $121.30 per transaction and $121.36 per recipient, Scpharmaceuticals Inc.'s Program Year 2024 total comes to $1,622,083.11 across 13,372 transactions and 13,366 physicians and teaching hospitals. In the CMS Open Payments database that is good for rank #500 of 1,925 companies, a comparatively small 0.0% slice of all industry payments reported nationwide for the year.

125 transactions worth $380.4K make "Compensation for Services Other Than Consulting" the top general-payment category in the 6-category breakdown below, 38.8% of General Payments (see our methodology for how research and ownership payments are reported separately).

General Payment Breakdown by Type

Across 6 types of general payments, Scpharmaceuticals Inc.'s largest category was "Compensation for Services Other Than Consulting" at $380.4K - 38.8% of General Payments.

Scpharmaceuticals Inc. reports 6 general-payment categories - the top three are Compensation for Services Other Than Consulting (38.8%), Food and Beverage (37.0%), and Honoraria (11.5%). The remaining 3 categories make up 12.7% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.

How Scpharmaceuticals Inc. divides its payments

How the reported total splits across payment categories

1. Compensation for Services…$380.4K2. Food and Beverage$362.7K3. Honoraria$112.3K4. Space Rental or Facility …$53.2K5. Consulting Fee$44.6K6. Travel and Lodging$27.1K
Payment Type Amount Transactions
Compensation for Services Other Than Consulting $380.4K 125
Food and Beverage $362.7K 13,078
Honoraria $112.3K 16
Space Rental or Facility Fees $53.2K 18
Consulting Fee $44.6K 16
Travel and Lodging $27.1K 113

Recipient Concentration in General Payments

The five largest recipient relationships account for $195,456.35 (19.9%) of $980,363.67 in this company's General Payments records across 7,419 recipients.

General Payments scope note

Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.

Largest General-Payment relationships for Scpharmaceuticals Inc.

The five named recipients with the highest reported General Payments from this company

Billy Abraham$45.0KHunter Clay Champion Sr$44.3KDaniel Bensimhon$41.3KErika D Feller$36.1KVamsi Krishna$28.8K
  1. 1

    Billy Abraham

    $45,000.00 across 4 reported transactions

  2. 2

    Hunter Clay Champion Sr

    $44,291.86 across 18 reported transactions

  3. 3

    Daniel Bensimhon

    $41,250.93 across 25 reported transactions

  4. 4

    Erika D Feller

    $36,083.75 across 26 reported transactions

  5. 5

    Vamsi Krishna

    $28,829.81 across 49 reported transactions

Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.

Similarly Concentrated Companies

Companies whose General Payments are spread across recipients about as (un)evenly as Scpharmaceuticals Inc.'s, measured by the same HHI concentration index above, not by payment size.

What HHI 2,500 means here

2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Scpharmaceuticals Inc..

Companies with Similar Payment Volumes

Open a profile or compare a similar company's CMS-reported payment pattern with Scpharmaceuticals Inc..

Showing 6 of 1,924 companies with CMS-reported payment data.

Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer

This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.

View saved (companies)
Download Scpharmaceuticals Inc.'s data (CSV)
Embed this widget

Copy this snippet to embed a live-linked card on your own site.

Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.